202 related articles for article (PubMed ID: 37789342)
21. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
22. Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal.
Wang Z; Chen L; Ma Y; Li X; Hu A; Wang H; Wang W; Li X; Tian B; Dong J
J Nanobiotechnology; 2021 Aug; 19(1):243. PubMed ID: 34384429
[TBL] [Abstract][Full Text] [Related]
23. Insufficient radiofrequency ablation promotes hepatocellular carcinoma cell progression via autophagy and the CD133 feedback loop.
Wang X; Deng Q; Feng K; Chen S; Jiang J; Xia F; Ma K; Bie P
Oncol Rep; 2018 Jul; 40(1):241-251. PubMed ID: 29749472
[TBL] [Abstract][Full Text] [Related]
24. The synergistic antitumor activity of 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) and anti-PD-L1 antibody inducing immunogenic cell death.
Duan XC; Peng LY; Yao X; Xu MQ; Li H; Zhang SQ; Li ZY; Wang JR; Feng ZH; Wang GX; Liao A; Chen Y; Zhang X
Drug Deliv; 2021 Dec; 28(1):800-813. PubMed ID: 33866918
[TBL] [Abstract][Full Text] [Related]
25. Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy.
Shi L; Wang J; Ding N; Zhang Y; Zhu Y; Dong S; Wang X; Peng C; Zhou C; Zhou L; Li X; Shi H; Wu W; Long X; Wu C; Liao W
Nat Commun; 2019 Nov; 10(1):5421. PubMed ID: 31780645
[TBL] [Abstract][Full Text] [Related]
26. Pre-Induced ICD Membrane-Coated Carrier-Free Nanoparticles for the Personalized Lung Cancer Immunotherapy.
Li S; Jiang S; Rahman MSU; Mei J; Wang X; Jiang J; Chen Y; Xu S; Liu Y
Small Methods; 2023 May; 7(5):e2201569. PubMed ID: 36932898
[TBL] [Abstract][Full Text] [Related]
27. Insufficient radiofrequency ablation-induced autophagy contributes to the rapid progression of residual hepatocellular carcinoma through the HIF-1α/BNIP3 signaling pathway.
Xu WL; Wang SH; Sun WB; Gao J; Ding XM; Kong J; Xu L; Ke S
BMB Rep; 2019 Apr; 52(4):277-282. PubMed ID: 30940322
[TBL] [Abstract][Full Text] [Related]
28. Conventional amphotericin B elicits markers of immunogenic cell death on leukemic blasts, mediates immunostimulatory effects on phagocytic cells, and synergizes with PD-L1 blockade.
Kofla G; Radecke C; Frentsch M; Walther W; Stintzing S; Riess H; Bullinger L; Na IK
Oncoimmunology; 2022; 11(1):2068109. PubMed ID: 35496500
[TBL] [Abstract][Full Text] [Related]
29. FA-PEG decorated MOF nanoparticles as a targeted drug delivery system for controlled release of an autophagy inhibitor.
Shi Z; Chen X; Zhang L; Ding S; Wang X; Lei Q; Fang W
Biomater Sci; 2018 Sep; 6(10):2582-2590. PubMed ID: 30151542
[TBL] [Abstract][Full Text] [Related]
30. Blockage of the IDO1 pathway by charge-switchable nanoparticles amplifies immunogenic cell death for enhanced cancer immunotherapy.
Shi M; Zhang J; Wang Y; Han Y; Zhao X; Hu H; Qiao M; Chen D
Acta Biomater; 2022 Sep; 150():353-366. PubMed ID: 35843594
[TBL] [Abstract][Full Text] [Related]
31. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
32. Photothermal MnO
Chen Z; Zhang Q; Huang Q; Liu Z; Zeng L; Zhang L; Chen X; Song H; Zhang J
Int J Pharm; 2022 Apr; 617():121578. PubMed ID: 35176333
[TBL] [Abstract][Full Text] [Related]
33. A phenolic based tumor-permeated nano-framework for immunogenic cell death induction combined with PD-L1 immune checkpoint blockade.
Sun X; Zhang J; Xiu J; Zhao X; Yang C; Li D; Li K; Hu H; Qiao M; Chen D; Zhao X
Biomater Sci; 2022 Jul; 10(14):3808-3822. PubMed ID: 35670432
[TBL] [Abstract][Full Text] [Related]
34. Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy.
Voloshin T; Kaynan N; Davidi S; Porat Y; Shteingauz A; Schneiderman RS; Zeevi E; Munster M; Blat R; Tempel Brami C; Cahal S; Itzhaki A; Giladi M; Kirson ED; Weinberg U; Kinzel A; Palti Y
Cancer Immunol Immunother; 2020 Jul; 69(7):1191-1204. PubMed ID: 32144446
[TBL] [Abstract][Full Text] [Related]
35. Nonferrous Ferroptosis Inducer Manganese Molybdate Nanoparticles to Enhance Tumor Immunotherapy.
Lei H; Li Q; Pei Z; Liu L; Yang N; Cheng L
Small; 2023 Nov; 19(45):e2303438. PubMed ID: 37420331
[TBL] [Abstract][Full Text] [Related]
36. Synergistic combination of targeted nano-nuclear-reactors and anti-PD-L1 nanobodies evokes persistent T cell immune activation for cancer immunotherapy.
Zhu L; Li J; Guo Z; Kwok HF; Zhao Q
J Nanobiotechnology; 2022 Dec; 20(1):521. PubMed ID: 36496381
[TBL] [Abstract][Full Text] [Related]
37. Nanoengineering a metal-organic framework for osteosarcoma chemo-immunotherapy by modulating indoleamine-2,3-dioxygenase and myeloid-derived suppressor cells.
Fan Q; Zuo J; Tian H; Huang C; Nice EC; Shi Z; Kong Q
J Exp Clin Cancer Res; 2022 May; 41(1):162. PubMed ID: 35501823
[TBL] [Abstract][Full Text] [Related]
38. The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment.
Zhang P; Qin C; Liu N; Zhou X; Chu X; Lv F; Gu Y; Yin L; Liu J; Zhou J; Huo M
Biomaterials; 2022 May; 284():121518. PubMed ID: 35462305
[TBL] [Abstract][Full Text] [Related]
39. Nanotransferrin-Based Programmable Catalysis Mediates Three-Pronged Induction of Oxidative Stress to Enhance Cancer Immunotherapy.
Bai S; Lu Z; Jiang Y; Shi X; Xu D; Shi Y; Lin G; Liu C; Zhang Y; Liu G
ACS Nano; 2022 Jan; 16(1):997-1012. PubMed ID: 34928122
[TBL] [Abstract][Full Text] [Related]
40. Tailor-Made Autophagy Cascade Amplification Polymeric Nanoparticles for Enhanced Tumor Immunotherapy.
Long X; Wang H; Yan J; Li Y; Dong X; Tian S; Sun Y; Luo K; He B; Liang Y
Small; 2023 Jun; 19(24):e2207898. PubMed ID: 36932938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
